Antimicrobial Resistance

Veterinary Clinics of North America - Small Animal Practice

Volumn 36, Issue 5, 2006, Pages 987-1001

  Clarke, Cyril R ^a  

^a OKLAHOMA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIINFECTIVE AGENT; CEFALOTIN; CEPHALOSPORIN; CHLORAMPHENICOL; CIPROFLOXACIN; CLINDAMYCIN; CLOXACILLIN; COTRIMOXAZOLE; DOXYCYCLINE; ENROFLOXACIN; ERYTHROMYCIN; GENTAMICIN; LINCOSAMIDE; LINEZOLID; MACROLIDE; MARBOFLOXACIN; METICILLIN; OXACILLIN; OXYTETRACYCLINE; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; STREPTOMYCIN; TEICOPLANIN; TETRACYCLINE; UNINDEXED DRUG;

ANTIBIOTIC RESISTANCE; DOMESTIC ANIMAL; DRUG EXPOSURE; DRUG USE; MICROBIAL GENETICS; MICROORGANISM; NONHUMAN; REVIEW; SURVIVAL; VETERINARY MEDICINE; ZOONOSIS;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIA; DRUG RESISTANCE, BACTERIAL; VETERINARY DRUGS;

ANIMALIA;

EID: 33748519837     PISSN: 01955616     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cvsm.2006.05.002     Document Type: Review

References (48)

1. Cosgrove S. The relationship between antimicrobial resistance and patient outcomes: mortality, length of hospital stay, and health care costs. Clin Infect Dis 42 (2006) S82-S89
2. McGowan J.E. Economic impact of antimicrobial resistance. Emerg Infect Dis 7 (2001) 286-292 [Erratum in Emerg Infect Dis 2001;7:765]
3. Bryson V., and Demerec M. Patterns of resistance to antimicrobial agents. Ann NY Acad Sci 53 (1950) 283-289
4. Demerec M. Origin of bacterial resistance to antibiotics. J Bacteriol 56 (1948) 63-74
5. Putman M., Van Veen H., and Konings W. Molecular properties of bacterial multidrug transporters. Microbiol Mol Biol Rev 64 (2000) 672-693
6. Mallea M., Chevalier J., Bornet C., et al. Porin alteration and active efflux: two in vivo drug resistance strategies used by Enterobacter aerogenes. Microbiology 144 (1998) 3003-3009
7. Snyder L., and Champness W. Conjugation. Molecular genetics of bacteria (1997), ASM Press, Washington (DC) 129-146
8. Snyder L., and Champness W. Transposition and nonhomologous recombination. Molecular genetics of bacteria (1997), ASM Press, Washington (DC) 195-213
9. Randall L., and Woodward M. The multiple antibiotic resistance (mar) locus and its significance. Res Vet Sci 72 (2002) 87-93
10. Webber M.A., and Piddock L.J.V. Absence of mutations in marRAB or soxRS in acrB-overexpressing fluoroquinolone-resistant clinical and veterinary isolates of Escherichia coli. Antimicrob Agents Chemother 45 (2001) 1550-1552
11. Giraud E., Cloeckaert A., Kerboeuf D., et al. Evidence for active efflux as the primary mechanism of resistance to ciprofloxacin in Salmonella enterica serovar Typhimurium. Antimicrob Agents Chemother 244 (2000) 1223-1228
12. Oethinger M., Podglajen I., Kern W., et al. Overexpression of the marA or soxS regulatory gene in clinical topoisomerase mutants of Escherichia coli. Antimicrob Agents Chemother 42 (1998) 2089-2094
13. Rich M., Deighton L., and Roberts L. Clindamycin-resistance in methicillin-resistant Staphylococcus aureus isolated from animals. Vet Microbiol 111 (2005) 237-240
14. Prescott J.F., Hanna W.J.B., Reid-Smith R., et al. Antimicrobial drug use and resistance in dogs. Can Vet J 43 (2002) 107
15. Cohn L., Gary A., Fales W., et al. Trends in fluoroquinolone resistance of bacteria isolated from canine urinary tracts. J Vet Diagn Invest 15 (2003) 338-343
16. Normand E., Gibson N., Taylor D., et al. Trends of antimicrobial resistance in bacterial isolates from a small animal referral hospital. Vet Rec 146 (2000) 151-155
17. Normand E., Gibson N., Reid S., et al. Antimicrobial-resistance trends in bacterial isolates from companion-animal community practice in the UK. Prev Vet Med 46 (2000) 267-278
18. Meunier D., Acar J., Martel J., et al. A seven-year survey of susceptibility to marbofloxacin of pathogenic strains isolated from pets. Int J Antimicrob Agents 24 (2004) 592-598
19. Ganiere J., Medaille C., and Mangion C. Antimicrobial drug susceptibility of Staphylococcus intermedius clinical isolates from canine pyoderma. J Vet Med B Infect Dis Vet Public Health 52 (2005) 25-31
20. Werckenthin C., Cardoso M., Martel J.-L., et al. Antimicrobial resistance in staphylococci from animals with particular reference to bovine Staphylococcus aureus, porcine Staphylococcus hyicus, and canine Staphylococcus intermedius. Vet Res 32 (2001) 341-362
21. Middleton J., Fales W., Luby C., et al. Surveillance of Staphylococcus aureus in veterinary teaching hospitals. J Clin Microbiol 43 (2005) 2916-2919
22. O'Mahony R., Abbott Y., Leonard F., et al. Methicillin-resistant Staphylococcus aureus (MRSA) isolated from animals and veterinary personnel in Ireland. Vet Microbiol 109 (2005) 285-296
23. Rich M., Roberts L., and Kearns A. Methicillin-resistant staphylococci isolated from animals. Vet Microbiol 105 (2005) 313-314
24. Hagman R., and Greko C. Antimicrobial resistance in Escherichia coli isolated from bitches with pyometra and from urine samples from other dogs. Vet Rec 157 (2005) 193-197
25. Rantala M., Lahti E., Kuhalampil J., et al. Antimicrobial resistance in Staphylococcus spp., Escherichia coli and Enterococcus spp. in dogs given antibiotics for chronic dermatological disorders, compared with non-treated control dogs. Acta Vet Scand 45 (2004) 37-45
26. Carattoli A., Lovari S., Franco A., et al. Extended-spectrum β-lactamases in Escherichia coli isolated from dogs and cats in Rome, Italy, from 2001 to 2003. Antimicrob Agents Chemother 49 (2005) 833-835
27. Seepersadsingh N., Adesiyun A.A., and Seebaransingh R. Prevalence and antimicrobial resistance of Salmonella spp. in non-diarrhoeic dogs in Trinidad. J Vet Med B Infect Dis Vet Public Health 51 (2004) 337-342
28. Butzler J. Campylobacter, from obscurity to celebrity. Clin Microbiol Infect 10 (2004) 868-876
29. Endtz H., Ruijs G., van Klingeren B., et al. Quinolone resistance in campylobacter isolated from man and poultry following the introduction of fluoroquinolones in veterinary medicine. J Antimicrob Chemother 27 (1991) 199-208
30. Guardabassi L., Schwarz S., and Lloyd D.H. Pet animals as reservoirs of antimicrobial-resistant bacteria. J Antimicrob Chemother 54 (2004) 321-332
31. Rankin S., Roberts S., O'Shea K., et al. Panton valentine leukocidin (PVL) toxin positive MRSA strains isolated from companion animals. Vet Microbiol 108 (2005) 145-148
32. Sannes M., Kuskowski M., and Johnson J. Antimicrobial resistance of Escherichia coli strains isolated from urine of women with cystitis or pyelonephritis and feces of dogs and healthy humans. J Am Vet Med Assoc 225 (2004) 368-373
33. Enoch D., Karas J., Slater J., et al. MRSA carriage in a pet therapy dog. J Hosp Infect 60 (2005) 186-188
34. Malik S., Peng H., and Barton M. Antibiotic resistance in staphylococci associated with cats and dogs. J Appl Microbiol 99 (2005) 1283-1293
35. Spellberg B., Powers J., Brass E., et al. Trends in antimicrobial drug development: implications for the future. Clin Infect Dis 38 (2004) 1279-1286
36. Wise R. The development of new antimicrobial agents. BMJ 317 (1998) 643-644
37. American Veterinary Medical Association. American Veterinary Medical Association judicious therapeutic use of antimicrobials. AVMA Scientific Activities Division, Food Safety Advisory Committee. Available at: www.avma.org/scienact/jtua/jtua98.asp. Accessed January 2006.
38. American Animal Hospital Association. AAHA guidelines on the judicious use of antimicrobials in dogs. AVMA Scientific Activities Division, Food Safety Advisory Committee. Available at: www.avma.org/scienact/jtua/canine/jtuacanine.asp. 2001. Accessed January 2006.
39. American Association of Feline Practitioners. American Association of Feline Practitioners basic guidelines of judicious therapeutic use of antimicrobials in cats. AVMA Scientific Activities Division, Food Safety Advisory Committee. Available at: www.avma.org/scienact/jtua/feline/jtuafeline.asp. 2004. Accessed January 2006.
40. Gonzales R., Bartlett J.G., Besser R.E., et al. Principles of appropriate antibiotic use for treatment of nonspecific upper respiratory tract infections in adults: background. Ann Intern Med 134 (2001) 490-494
41. Bissett L. Controlling the risk of MRSA infection: screening and isolating patients. Br J Nurs 14 (2005) 386-390
42. Eveillard M., Eb F., Tramier B., et al. Evaluation of the contribution of isolation precautions in prevention and control of multi-resistant bacteria in a teaching hospital. J Hosp Infect 47 (2001) 116-124
43. Drlica K. The mutant selection window and antimicrobial resistance. J Antimicrob Chemother 52 (2003) 11-17
44. Zhao X., and Drlica K. Restricting the selection of antibiotic-resistant mutants: a general strategy derived from fluoroquinolone studies. Clin Infect Dis 33(Suppl) (2001) S147-S156
45. Smith H.J., Nichol K.A., Hoban D.J., et al. Stretching the mutant prevention concentration (MPC) beyond its limits. J Antimicrob Chemother 51 (2003) 1323-1325
46. Katchman E., Milo G., Paul M., et al. Three-day vs longer duration of antibiotic treatment for cystitis in women: systematic review and meta-analysis. Am J Med 118 (2005) 1196-1207
47. Centers for Disease Control. Food and Drug Administration, National Institutes of Health. A public health plan to combat antimicrobial resistance. Part 1: domestic issues. Interagency Task Force on Antimicrobial Resistance. Available at: www.cdc.gov/drugresistance/actionplan/. 2001. Accessed January 2006.
48. Centers for Disease Control. Food and Drug Administration, US Department of Agriculture. National antimicrobial resistance monitoring system (NARMS): enteric bacteria. National Center for Infectious Diseases. Available at: www.cdc.gov/narms/. 1996. Accessed January 2006.